[go: up one dir, main page]

WO2012088607A1 - Procédé pour la préparation d'un sel de tréprostinil - Google Patents

Procédé pour la préparation d'un sel de tréprostinil Download PDF

Info

Publication number
WO2012088607A1
WO2012088607A1 PCT/CA2011/050804 CA2011050804W WO2012088607A1 WO 2012088607 A1 WO2012088607 A1 WO 2012088607A1 CA 2011050804 W CA2011050804 W CA 2011050804W WO 2012088607 A1 WO2012088607 A1 WO 2012088607A1
Authority
WO
WIPO (PCT)
Prior art keywords
treprostinil
process according
water
solution
aqueous basic
Prior art date
Application number
PCT/CA2011/050804
Other languages
English (en)
Inventor
Walter Giust
Fabio Souza
Jan Oudenes
Boris Gorin
Elena Bejan
Original Assignee
Alphora Research Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphora Research Inc. filed Critical Alphora Research Inc.
Priority to US13/520,872 priority Critical patent/US9550716B2/en
Publication of WO2012088607A1 publication Critical patent/WO2012088607A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation

Definitions

  • This specification relates to a process for treprostinil salt preparation.
  • Prostacyclin derivatives are useful pharmaceutical compounds possessing pharmacological activities such as platelet aggregation inhibition, gastric secretion reduction, lesion inhibition, vasodilation and bronchodilation.
  • Treprostinil is a prostacyclin analogue, having the following chemical structure:
  • Treprostinil sodium solution is marketed as Remodulin® and Tyvaso® for treatment of pulmonary arterial hypertension.
  • treprostinil sodium can be difficult, as the salt is soluble in water and difficult to precipitate, while the treprostinil acid is only sparingly soluble in water.
  • Salts of a compound can be useful due in part to their increased stability, bioavailability and solubility in water. Availability of treprostinil salt can also help in preparation of a formulation, including a pharmaceutical formulation.
  • the specification relates to a process for preparing a treprostinil salt, comprising :
  • FIGURE 1 shows a powder X-ray diffraction spectrum of treprostinil sodium obtained according to the reaction described herein.
  • the specification relates to a process for preparing a treprostinil salt, the process containing the steps of:
  • the water-miscible organic solvent used for dissolving treprostinil is not particularly limited, and can contain one or more functional groups, as long as the organic solvent is miscible and can form a solution with water.
  • the water-miscible organic solvent is a water-miscible ketone solvent, water-miscible alcohol or water-miscible ether.
  • the water- miscible organic solvent is a water-miscible ketone solvent.
  • the number of carbon atoms in the water-miscible ketone solvent is not particularly limited but can be any number, as long as the water-miscible ketone solvent is miscible in water.
  • the water-miscible ketone solvent contains from 3 to 8 carbon atoms.
  • the water-miscible ketone solvent is a hydrocarbon based water-miscible ketone solvent.
  • hydrocarbon based water-miscible ketone solvent contains a ketone functional group and a hydrocarbon chain having carbon and hydrogen atoms.
  • the water-miscible ketone solvent is a linear or branched alkyl ketone.
  • the number of carbon atoms in the alkyl ketone is not particularly limited and contain, for example and without limitation, 3 to 6 carbon atoms.
  • the water-miscible solvent is acetone.
  • Examples of water-miscible ketone solvents for use in preparation of treprostinil salt can include, for example and without limitation, acetone, butanone, 2-pentanone, 3-pentanone, methyl isopropyl ketone, 2-hexanone, 3-hexanone, methyl isobutyl ketone (MIBK), ethyl isopropyl ketone, cyclopentanone, 2-methyl cyclopentanone, 3-methyl cyclopentanone, cyclohexanone and others.
  • MIBK methyl isobutyl ketone
  • the water-miscible organic solvent is a water- miscible alcohol.
  • the number of carbon atoms in the water-miscible alcohol is not particularly limited but can be any number, as long as the alcohol is miscible in water.
  • the water-miscible alcohol contains from 3 to 8 carbon atoms.
  • the water-miscible alcohol is a hydrocarbon based water- miscible alcohol.
  • a hydrocarbon based water-miscible alcohol contains an alcohol functional group and a hydrocarbon chain having carbon and hydrogen atoms.
  • the water-miscible alcohol is a linear or branched alkyl alcohol.
  • the number of carbon atoms in the linear or branched hydrocarbon based alcohol is not particularly limited and contain, for example and without limitation, 3 to 6 carbon atoms.
  • the water-miscible alcohol is methanol, ethanol, propanol, isopropanol and others.
  • water-miscible organic solvents can also be used.
  • examples of other water-miscible organic solvents can include, for example and without limitation, tetrahydrofuran, acetonitrile and others.
  • two or more organic solvents can also be used so long the organic solvents together are miscible in water.
  • the ratio of treprostinil to the water-miscible organic solvent as described herein is not particularly limited. In one embodiment, for example and without limitation, the ratio of treprostinil to the water-miscible organic solvent is
  • treprostinil 1 g of treprostinil to from 5 to 50 mL of the water-miscible organic solvent.
  • the ratio of treprostinil to the water-miscible organic solvent is, for example and without limitation, 1 g of treprostinil to from 15 to 30 mL of the water-miscible organic solvent.
  • the aqueous basic solution for reaction with treprostinil to form treprostinil salt contains an aqueous solution and a base, which can deprotonate carboxylic acid moiety of treprostinil .
  • the base in the aqueous basic solution for use in the reaction described herein is not particularly limited and contains an anion and an alkali metal cation.
  • the anion is hydroxide, carbonate or bicarbonate anion.
  • the alkali metal cation for use in the reaction described herein can be, for example and without limitation, lithium, sodium or potassium .
  • the aqueous basic solution contains sodium hydroxide for reaction with treprostinil to form treprostinil sodium .
  • the concentration of the base in the aqueous basic solution for reaction with treprostinil is not particularly limited. Sufficient concentration of the aqueous basic solution can be used to allow reaction with treprostinil and to allow formation of treprostinil salt. In one embodiment, for example and without limitation, the base in the aqueous basic solution has a concentration of from about
  • the base in the aqueous basic solution has a concentration of from about 5 molar.
  • the mole ratio of the base in the aqueous basic solution to treprostinil in the treprostinil solution is not particularly limited. The mole ratio used can be chosen to maximize yield, by reaction of the base with treprostinil and allowing crystallization of treprostinil salt. In general, the ratio of the base to treprostinil used allows for deprotonation of treprostinil.
  • the mole ratio of base in the basic solution to treprostinil in the treprostinil solution ranges from 1 : 1 to 2 : 1. In another embodiment, the mole ratio of base in the basic solution to treprostinil in the treprostinil solution is, for example and without limitation, about 1.05 : 1, 1.1 : 1 or 1.2 : 1.
  • the volumetric ratio of the water-miscible organic solvent to the aqueous basic solution for preparation of treprostinil salt from treprostinil is not particularly limited.
  • the volumetric ratio can be set to maximize yield and/or quality of treprostinil salt obtained.
  • the volumetric ratio of the water-miscible organic solvent to the aqueous basic solution is from 10 : 1 to 70 : 1.
  • the volumetric ratio of the water-miscible organic solvent to the aqueous basic solution is, for example and without limitation, about 40 : 1.
  • the process for preparation of treprostinil salt from treprostinil is carried out by warming the treprostinil solution prior to reaction of the treprostinil solution with the aqueous basic solution.
  • the temperature the treprostinil solution is warmed is not particularly limited. In one embodiment, for example and without limitation, the treprostinil solution is warmed up to about 60°C prior to reacting it with the aqueous basic solution. In another embodiment, the treprostinil solution is warmed, for example and without limitation, up to about 30°C prior to reacting it with the aqueous basic solution.
  • the temperature the treprostinil solution is warmed can include all temperature values between those noted above.
  • the addition of reactants for performing the reaction of treprostinil in the treprostinil solution with the aqueous basic solution is not particularly limited.
  • the aqueous basic solution is added to the treprostinil solution for reaction with treprostinil .
  • the temperature for carrying out the reaction of treprostinil in the treprostinil solution with the aqueous basic solution is not particularly limited. In one embodiment, for example and without limitation, the reaction of the treprostinil solution with the aqueous basic solution is carried out at an internal temperature below about 60°C. In another embodiment, the reaction of the treprostinil solution with the aqueous basic solution is carried out at an internal temperature, for example and without limitation, below about 30°C.
  • the temperature for carrying out the reaction can include all values between those noted above.
  • the reaction of treprostinil in the treprostinil solution with the aqueous basic solution as described herein can be carried out, for example and without limitation, by agitating the reaction.
  • the rate of agitation for carrying out the reaction is not particularly limited.
  • the rate of agitation can be set to maximize yield and/or quality of treprostinil salt.
  • agitation is continued even after allowing crystallization of treprostinil salt.
  • the time period for the agitation is also not particularly limited and can be, for example and without limitation, for at least about 4 hours.
  • the agitation is carried out, for example and without limitation, for about 1 hour.
  • the temperature at which the reaction mixture is agitated after allowing crystallization of treprostinil salt and prior to collecting treprostinil salt is not particularly limited. In one embodiment, for example and without limitation, the reaction mixture is agitated at room temperature.
  • the reaction mixture is cooled prior to collecting treprostinil salt.
  • the temperature to which the reaction mixture is cooled prior to collecting treprostinil salt is not particularly limited and can be, for example and without limitation, from 0 to 15 °C. In another embodiment, the temperature to which the reaction mixture is cooled prior to collecting treprostinil salt is, for example and without limitation, 0 to 5 °C. In a further embodiment, agitation can continued during the cooling of the reaction mixture.
  • the time period for which the reaction mixture is cooled and/or agitated prior to collecting the crystals is not particularly limited. In one embodiment, for example and without limitation, the reaction mixture is cooled and agitated for about 5 hours. In another embodiment, the reaction mixture is cooled and agitated, for example and without limitation, about 1 hour.
  • the method of collecting treprostinil salt formed after completion of the reaction is not particularly limited.
  • treprostinil salt is collected by vacuum filtration.
  • treprostinil salt collected is dried.
  • the treprostinil sodium can be obtained from intermediate 1, as shown in scheme 1.
  • Intermediate 1 is alkylated then hydrolyzed to obtain treprostinil.
  • the reaction product obtained after alkylation can be, for example and without limitation, an ester.
  • the treprostinil obtained is dissolved in a water-miscible organic solvent and reacted with an aqueous basic solution, as described herein, to form treprostinil sodium .
  • the treprostinil sodium is allowed to crystallize and then collected.
  • intermediate 1 is not particularly limited and different methods can be used depending upon the synthetic route adopted.
  • intermediate 1 is alkylated using a halo-acetate or an acetate having a leaving group at the alkyl moiety.
  • the halo-acetate can be, for example and without limitation, bromoacetate or chloroacetate.
  • the solvent for the alkylation reaction is not particularly limited and can be determined.
  • the alkylation reaction is carried out in acetone.
  • the time and temperature for carrying out the alkylation reaction are also not particularly limited, and can be determined.
  • the reaction was carried out for about from 5 to 10 hours.
  • the reaction temperature can be, for example and without limitation, room temperature or from room temperature to about 50°C. Upon completion, the reaction is worked up and purified using standard methodology to obtain treprostinil.
  • Example 1 Treprostinil preparation
  • Example 2 Treprostinil Sodium salt preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention a pour objet un procédé de préparation d'un sel de tréprostinil. Le procédé implique l'étape de dissolution de tréprostinil dans un solvant organique miscible à l'eau pour former une solution de tréprostinil. La solution de tréprostinil est mise à réagir avec une solution basique aqueuse contenant un cation métallique alcalin pour former un sel de tréprostinil. On laisse alors la cristallisation du sel de tréprostinil avoir lieu, et ensuite on recueille le sel de tréprostinil formé.
PCT/CA2011/050804 2010-12-30 2011-12-22 Procédé pour la préparation d'un sel de tréprostinil WO2012088607A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/520,872 US9550716B2 (en) 2010-12-30 2011-12-22 Process for treprostinil salt preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2726599A CA2726599C (fr) 2010-12-30 2010-12-30 Procede de preparation de sel a partir de treprostinil
CA2726599 2010-12-30

Publications (1)

Publication Number Publication Date
WO2012088607A1 true WO2012088607A1 (fr) 2012-07-05

Family

ID=46382135

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2011/050804 WO2012088607A1 (fr) 2010-12-30 2011-12-22 Procédé pour la préparation d'un sel de tréprostinil

Country Status (3)

Country Link
US (1) US9550716B2 (fr)
CA (1) CA2726599C (fr)
WO (1) WO2012088607A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013104318A1 (fr) * 2012-01-10 2013-07-18 上海天伟生物制药有限公司 Forme cristalline d'un analogue de prostaglandine, son procédé de préparation et son utilisation
WO2014159050A1 (fr) * 2013-03-14 2014-10-02 United Therapeutics Corporation Formes solides de tréprostinil
US9029607B2 (en) 2010-07-22 2015-05-12 Alphora Research Inc. Protected aldehydes for use as intermediates in chemical syntheses, and processes for their preparation
WO2016055819A1 (fr) 2014-10-08 2016-04-14 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Procédé de préparation de tréprostinil
JP2016516693A (ja) * 2013-03-15 2016-06-09 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの塩
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9550716B2 (en) 2010-12-30 2017-01-24 Eon Labs, Inc. Process for treprostinil salt preparation
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
WO2020233588A1 (fr) * 2019-05-21 2020-11-26 江苏众强药业有限公司 Nouvelle forme cristalline d'un sel de tréprostinil sodique et son procédé de préparation
JP2021098689A (ja) * 2019-12-19 2021-07-01 チャイロゲート インターナショナル インク．Ｃｈｉｒｏｇａｔｅ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃ． 超高純度トレプロスチニルを調製するための効率的な結晶化プロセス及びそれから調製された結晶
JP2022500468A (ja) * 2018-09-18 2022-01-04 イーライ リリー アンド カンパニー トレプロスチニルのエルブミン塩

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2778274T3 (es) 2014-10-20 2020-08-10 United Therapeutics Corp Síntesis de productos intermedios para producir derivados de prostaciclina
US20160243064A1 (en) * 2015-02-21 2016-08-25 Gavis Pharmaceuticals Novel oral pharmaceutical compositions of treprostinil
CA3038276A1 (fr) 2016-09-26 2018-03-29 United Therapeutics Corporation Promedicaments de treprostinil
HU231296B1 (hu) * 2018-03-09 2022-09-28 Chinoin Zrt Eljárás treprostinil-dietanol-amin só B polimorf formájának előállítására
WO2021041320A1 (fr) 2019-08-23 2021-03-04 United Therapeutics Corporation Promédicaments de tréprostinil
CN115916212A (zh) 2020-04-17 2023-04-04 联合治疗公司 曲前列尼尔用于治疗间质性肺病
CA3180230A1 (fr) 2020-06-09 2021-12-16 Hitesh Batra Promedicaments a base de fumaryle dicetopiperidine de treprostinil
KR20230134480A (ko) 2020-12-14 2023-09-21 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
EP4301372A1 (fr) 2021-03-03 2024-01-10 United Therapeutics Corporation Composition de poudre sèche de treprostinil et son promédicament et comprenant en outre de l'(e)-3,6-bis[4-(n-carbonyl-2-propényl)amidobutyl]-2,5-dicétopipérazine (fdkp)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486598A (en) * 1982-02-22 1984-12-04 The Upjohn Company Carbacyclin analogs
US20090163738A1 (en) * 2007-12-17 2009-06-25 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1201712A (fr) 1980-02-28 1986-03-11 Paul A. Aristoff Analogues de la carbacycline
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4537346A (en) 1983-10-17 1985-08-27 Standard-Thomson Corporation Fail-safe oil flow control apparatus
DE9309741U1 (de) 1993-06-30 1993-08-26 Filterwerk Mann & Hummel Gmbh, 71638 Ludwigsburg Wärmetauscher
SE9502189D0 (sv) 1995-06-16 1995-06-16 Tetra Laval Holdings & Finance Plattvärmeväxlare
JP3717053B2 (ja) 1997-10-24 2005-11-16 ユナイテッド セラピューティックス コーポレイション プロスタサイクリン誘導体の立体選択的合成法
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
DE19750814C5 (de) 1997-11-17 2005-08-18 Modine Manufacturing Co., Racine Wärmetauscher, insbesondere Ölkühler
US6700025B2 (en) 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
FR2853725B1 (fr) 2003-04-09 2017-06-09 Valeo Thermique Moteur Sa Module de refroidissement a derivation, notamment pour vehicule automobile
JP5043433B2 (ja) * 2003-05-22 2012-10-10 ユナイテッド セラピューティクス コーポレイション プロスタサイクリン類似体の送達のための化合物及び方法
US7371888B2 (en) 2004-02-18 2008-05-13 Metabolex, Inc. α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents
EP2200650B1 (fr) 2007-09-07 2016-01-06 United Therapeutics Corporation Tampons présentant une activité bactéricide sélective contre les bactéries à gram négatif et leurs procédés d'utilisation
US8481782B2 (en) 2010-06-03 2013-07-09 United Therapeutics Corporation Treprostinil production
CA2710726C (fr) 2010-07-22 2016-02-23 Alphora Research Inc. Synthese de treprostinil et intermediaires utiles pour celle-ci
CA2726599C (fr) 2010-12-30 2017-07-25 Alphora Research Inc. Procede de preparation de sel a partir de treprostinil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486598A (en) * 1982-02-22 1984-12-04 The Upjohn Company Carbacyclin analogs
US20090163738A1 (en) * 2007-12-17 2009-06-25 United Therapeutics Corporation Process to prepare treprostinil, the active ingredient in remodulin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LI, J. ET AL., MINI-REVIEWS IN MEDICINAL CHEMISTRY, vol. 4, 2004, pages 207 - 233 *

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029607B2 (en) 2010-07-22 2015-05-12 Alphora Research Inc. Protected aldehydes for use as intermediates in chemical syntheses, and processes for their preparation
US9550716B2 (en) 2010-12-30 2017-01-24 Eon Labs, Inc. Process for treprostinil salt preparation
US9278903B2 (en) 2012-01-10 2016-03-08 Shanghai Techwell Biopharmaceutical Co., Ltd. Crystal form of prostaglandin analogue, and preparation method and use thereof
WO2013104318A1 (fr) * 2012-01-10 2013-07-18 上海天伟生物制药有限公司 Forme cristalline d'un analogue de prostaglandine, son procédé de préparation et son utilisation
US11339139B2 (en) 2013-01-11 2022-05-24 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9776982B2 (en) 2013-01-11 2017-10-03 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10450290B2 (en) 2013-01-11 2019-10-22 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11505535B2 (en) 2013-01-11 2022-11-22 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10344012B2 (en) 2013-01-11 2019-07-09 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11958822B2 (en) 2013-01-11 2024-04-16 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US11046666B2 (en) 2013-01-11 2021-06-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9845305B2 (en) 2013-01-11 2017-12-19 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10752605B2 (en) 2013-01-11 2020-08-25 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US10167247B2 (en) 2013-03-14 2019-01-01 United Therapeutics Corporation Solid forms of treprostinil
KR102347340B1 (ko) 2013-03-14 2022-01-06 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐의 고체 형태
KR20150126908A (ko) * 2013-03-14 2015-11-13 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐의 고체 형태
US9822057B2 (en) 2013-03-14 2017-11-21 United Therapeutics Corporation Solid forms of treprostinil
WO2014159050A1 (fr) * 2013-03-14 2014-10-02 United Therapeutics Corporation Formes solides de tréprostinil
KR102405650B1 (ko) 2013-03-15 2022-06-03 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐의 염
US9988334B2 (en) 2013-03-15 2018-06-05 United Therapeutics Corporation Salts of treprostinil
US9701611B2 (en) 2013-03-15 2017-07-11 United Therapeutics Corporation Salts of treprostinil
US11236035B2 (en) 2013-03-15 2022-02-01 United Therapeutics Corporation Salts of treprostinil
KR20210063453A (ko) * 2013-03-15 2021-06-01 유나이티드 세러퓨틱스 코오포레이션 트레프로스티닐의 염
JP2019052152A (ja) * 2013-03-15 2019-04-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの塩
CN109608326A (zh) * 2013-03-15 2019-04-12 联合治疗公司 曲前列环素的盐
EP2970081A4 (fr) * 2013-03-15 2016-10-12 United Therapeutics Corp Sels de tréprostinil
JP2016516693A (ja) * 2013-03-15 2016-06-09 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの塩
CN107001221A (zh) * 2014-10-08 2017-08-01 奇诺因药物和化学工厂私人有限公司 用于制备曲前列尼尔的方法
US11098001B2 (en) * 2014-10-08 2021-08-24 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Process for the preparation of treprostinil
WO2016055819A1 (fr) 2014-10-08 2016-04-14 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Procédé de préparation de tréprostinil
US11724979B2 (en) 2014-10-08 2023-08-15 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Process for the preparation of treprostinil
TWI761299B (zh) * 2014-10-08 2022-04-21 匈牙利商齊諾應醫藥及化學品股份有限公司 製備曲前列環素（ｔｒｅｐｒｏｓｔｉｎｉｌ）之方法
TWI761731B (zh) * 2014-10-08 2022-04-21 匈牙利商齊諾應醫藥及化學品股份有限公司 曲前列環素（ｔｒｅｐｒｏｓｔｉｎｉｌ）的鈉鹽單水合物及其製法
JP2017531661A (ja) * 2014-10-08 2017-10-26 キノイン・ジヨージセル・エーシユ・ベジエーセテイ・テルメーケク・ジヤーラ・ゼー・エル・テー トレプロスチニルの製造方法
CN107001221B (zh) * 2014-10-08 2021-05-25 奇诺因药物和化学工厂私人有限公司 用于制备曲前列尼尔的方法
US10246403B2 (en) 2015-06-17 2019-04-02 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10053414B2 (en) 2015-06-17 2018-08-21 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10703706B2 (en) 2015-06-17 2020-07-07 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10464877B2 (en) 2015-06-17 2019-11-05 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11866402B2 (en) 2015-06-17 2024-01-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9957220B2 (en) 2015-06-17 2018-05-01 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10988435B2 (en) 2015-06-17 2021-04-27 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11802105B2 (en) 2015-06-17 2023-10-31 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10759733B2 (en) 2015-06-17 2020-09-01 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9701616B2 (en) 2015-06-17 2017-07-11 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11034645B2 (en) 2015-06-17 2021-06-15 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US11407707B2 (en) 2015-06-17 2022-08-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10464878B2 (en) 2015-06-17 2019-11-05 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
JP7194817B2 (ja) 2018-09-18 2022-12-22 イーライ リリー アンド カンパニー トレプロスチニルのエルブミン塩
JP2022500468A (ja) * 2018-09-18 2022-01-04 イーライ リリー アンド カンパニー トレプロスチニルのエルブミン塩
US12102610B2 (en) 2018-09-18 2024-10-01 Eli Lilly And Company Treprostinil salt
WO2020233588A1 (fr) * 2019-05-21 2020-11-26 江苏众强药业有限公司 Nouvelle forme cristalline d'un sel de tréprostinil sodique et son procédé de préparation
JP7233114B2 (ja) 2019-12-19 2023-03-06 チャイロゲート インターナショナル インク． 超高純度トレプロスチニルを調製するための効率的な結晶化プロセス及びそれから調製された結晶
JP2021098689A (ja) * 2019-12-19 2021-07-01 チャイロゲート インターナショナル インク．Ｃｈｉｒｏｇａｔｅ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃ． 超高純度トレプロスチニルを調製するための効率的な結晶化プロセス及びそれから調製された結晶

Also Published As

Publication number Publication date
US9550716B2 (en) 2017-01-24
US20140024856A1 (en) 2014-01-23
CA2726599A1 (fr) 2012-06-30
CA2726599C (fr) 2017-07-25

Similar Documents

Publication Publication Date Title
CA2726599C (fr) Procede de preparation de sel a partir de treprostinil
EP3498695B1 (fr) Procédé de synthèse d'acide 3- (difluorométhyl)-1-méthyl-1 h-pyrazole-4-carboxylique
CA2827455C (fr) Procede pour la production d'un sel de pemetrexed
ES2716748T3 (es) Procedimientos de preparación de compuestos, tales como 3-arilbutanales, útiles en la síntesis de medetomidina
JP5785622B2 (ja) その構造内にグルタミン酸部分を有する葉酸拮抗薬の新規な製造方法
EP2328884A2 (fr) Procédé de préparation de ranélate de strontium
KR101773995B1 (ko) 2-티오히스티딘 및 이것의 유사체의 합성법
EP1674463A1 (fr) Sels de rabeprazole sous forme crystalline hydratée
CN101575286B (zh) 一种辛伐他汀铵盐的合成方法及所用中间体及其制备方法
RU2007146394A (ru) Способы получения гетероциклических соединений
JP6124562B2 (ja) ４′−［［２−ｎ−プロピル−４−メチル−６−（１−メチルベンズイミダゾール−２−イル）−ベンズイミダゾール−１−イル］−メチル］−ビフェニル−２−カルボン酸のアンモニウム塩の結晶
US20130109865A1 (en) Methods of preparing 1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone
JP4790901B2 (ja) ４−アミノ−５−シアノイミダゾール誘導体及びその中間体の製造方法
WO2006116007A2 (fr) Procedes de synthese de composes de dicarbamate et de produits intermediaires dans la formation de ces derniers
JP3899626B2 (ja) ２−メルカプトチアゾ−ルの製法
US20190010141A1 (en) Process for the synthesis of efinaconazol
PL209729B1 (pl) Sposób wytwarzania chlorowodorku 2-[(2,3,4-trihydroksyfenylo)metylo]hydrazydu D,L-seryny
KR102500243B1 (ko) 5-(c1~c4 알킬) 테트라졸의 합성방법
WO2008018843A1 (fr) Procédé de production de formes de sel utiles de composés de biphényl-tétrazole
WO2007129184A2 (fr) Procédé amélioré de préparation de sodium de phénytoïne
EP1963309B1 (fr) Procédé de production de sels métalliques de losartan
WO2011150950A1 (fr) Sels de 2-méthyl-5-vinylpyridinium
WO2006098705A1 (fr) Procede de fabrication de composes du biphenyl-tetrazole
CN102690201A (zh) 一种辛伐他汀中间体及其制备方法
EP2476670A1 (fr) Seuls solides stabiles de l'ambrisentane

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11854309

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011854309

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13520872

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11854309

Country of ref document: EP

Kind code of ref document: A1